TABLE 3.
Association between Δln(GAA) and the outcomes of Δln(SAM), Δln(SAH), Δln(tHcys), and Δln(tCys) by treatment group in Bangladeshi adults participating in a folic acid and creatine randomized, controlled trial1
| β (95% CI ) |
β (95% CI) |
|||||
| Outcome | Placebo (n = 101) | Cr (n = 101) | P(Cr vs. placebo)2 | FA (n = 130) | Cr+FA (n = 102) | P(Cr+Fa vs. FA)2 |
| Δ ln(SAM)3 | 0.10 (−0.16, 0.36) | −0.09 (−0.28, 0.11) | 0.26 | −0.02 (−0.21, 0.18) | 0.02 (−0.14, 0.19) | 0.73 |
| Δ ln(SAH)4 | 0.55 (0.00, 1.10) | 0.07 (−0.35, 0.49) | 0.16 | −0.10 (−0.54, 0.34) | 0.31 (−0.03, 0.65) | 0.14 |
| Δ ln(tHcys) | 0.03 (−0.17, 0.23) | −0.12 (−0.28, 0.05) | 0.26 | −0.08 (−0.23, 0.08) | 0.30 (0.17, 0.43) | 0.0003 |
| Δ ln(tCys) | −0.03 (−0.14, 0.08) | −0.03 (−0.13, 0.07) | 0.98 | 0.07 (−0.02, 0.15) | 0.16 (0.08, 0.24) | 0.12 |
β (95% CI) is the estimated regression coefficient of Δln(GAA) from linear regression models. All models are adjusted for ln(baseline GAA) and ln(baseline outcome). Δ = ln(week 12) – ln(baseline). Cr, 3 g/d creatine group; Cr+FA, 3 g/d creatine plus 400 μg/d folic acid group; FA, 400 μg/d folic acid group; GAA, guanidinoacetate; SAH, s-adenosylhomocysteine; SAM, s-adenosylmethionine; tCys, total cysteine; tHcys, total homocysteine.
From Wald test for treatment group difference in covariate-adjusted regression coefficient.
Reduced sample size (placebo, n = 76; Cr, n = 89; FA, n = 118; Cr+FA, n = 93).
Reduced sample size (placebo, n = 68; Cr, n = 86; FA, n = 110; Cr+FA, n = 84).